Pharma in silica inc. announces today the closing of a $ 2,000,000 funding to continue the development of OpPacli™, an original nanomedicine developed to provide patients suffering from certain solid cancers with a well-tolerated and more efficient chemotherapy.
Read MoreadMare BioInnovations is pleased to announce it has achieved LEED® v4 certification for the conception and construction of Building 2 at the Montreal Innovation Centre. LEED (Leadership in Energy and Environmental Design) was developed by the U.S. Green Building Council (USGBC) and is administered in Canada by the Canada Green Building Council (CAGBC). LEED is the most widely used green building rating system in the world and an international symbol of excellence. Through design, construction, and operation practices that improve environmental and human health, LEED-certified buildings are helping to make the world more sustainable.
Read MoreA new made-in-B.C. Life Sciences and Biomanufacturing Strategy outlines how the Province will capitalize on the industry value chain from discovery through to clinical trials and manufacturing by supporting targeted investments in people and infrastructure. To help grow innovative local companies, the Province is investing $10 million in a new wet lab facility with adMare Bioinnovations.
Read MoreThe adMare Academy is proud to launch the BioInnovation Scientist (BIS) Program: Foundations. This online, cohort-based program will provide early-career scientists with fundamental knowledge in therapeutics development while simultaneously building their professional skills to succeed in the Canadian life sciences industry.
Read MoreThe Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced its expansion into Quebec with the location of their future Biomanufacturing Training Facility in Montreal.
Read MoreadMare BioInnovations (adMare) and Medicine by Design are pleased to announce their new memorandum of understanding (MOU) to support translation priorities, which will accelerate health innovation commercialization in the Toronto life sciences ecosystem and in Canada.
Read MoreVentus Therapeutics, Inc. announced today that the company has entered into an exclusive worldwide license agreement with Novo Nordisk A/S to develop and commercialize candidates from Ventus’ portfolio of peripherally-restricted NLRP3 inhibitors.
Read MoreIn celebration of Global Biotech Week, today at the national BIONATION 2022 conference, the leaders of Genome Canada and adMare BioInnovations announced a new strategic partnership to support the translation of genomics research into commercialization opportunities in healthcare.
Genomics-enabled precision health tools are speeding up diagnoses and improving health outcomes and disease management for Canadians.
adMare BioInnovations and the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are pleased to announce their new partnership to train industry-ready talent for Canada’s biopharmaceutical manufacturing sector.
Read MoreadMare BioInnovations and the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are pleased to announce their new partnership to train industry-ready talent for Canada’s biopharmaceutical manufacturing sector.
Read MoreMONTREAL, July 6, 2021 /CNW/ - A new made-in-Canada life sciences company, Nimium Therapeutics, has been launched to develop novel therapies for patients with cardiometabolic diseases.
Read MoreCALGARY, AB, May 17, 2021 /CNW/ - adMare BioInnovations ("adMare") and AazeinTx Inc. ("AazeinTx") have closed a global exclusive licensing transaction for a promising acute asthma treatment.
Read MoreTwo successful Canadian innovation organizations, CDRD, Canada’s national life sciences venture, and NEOMED Institute, a leading not-for-profit R&D organization building an innovation ecosystem in Montréal, are pleased to announce that effective today, they are bringing their respective capabilities and resources together under a new co-founded pan-Canadian enterprise, adMare BioInnovations.
Read More
